BioSante, Cell Genesys merger will provide cash for Phase III

BioSante Pharmaceuticals says that its planned merger with Cell Genesys will bring in between $20 million and $25 million, which can fund its development program for a gel to treat female sexual dysfunction. LibiGel is now in Phase III trials and the company expects to file for an approval in early 2011. "We would hope to close the merger somewhere between September 30 and October 30, and that will bring in between $20 and $25 million into BioSante, which will allow us to continue the program we have ongoing right now," CEO Stephen Simes told Bloomberg. Release | Report

Suggested Articles

Bristol Myers Squibb is teaming up with Repare Therapeutics to find new synthetic lethality targets in a deal that could be worth billions.

Biotech Orpheris has been given the FDA go-ahead for a phase 2 aimed at calming the cytokine storm sometimes caused by COVID-19.

PureTech plans to start a trial in the emerging population of patients who survive COVID-19 only to suffer lasting damage in the third quarter.